Enliven Therapeutics, Inc.
NASDAQ:ELVN
19.14 (USD) • At close June 2, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 124.117 | 100.141 | 75.536 | 110.024 | 130.365 | 4.936 | 7.382 | 9.671 |
| Short Term Investments
| 189.323 | 153.007 | 0 | 41.969 | 40.524 | 23.971 | 0 | 0 |
| Cash and Short Term Investments
| 313.44 | 253.148 | 75.536 | 110.024 | 130.365 | 28.907 | 7.382 | 9.671 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 4.687 | 13.003 | 2.217 | 0.646 | 0.222 | 1.717 | 0.323 | 0.552 |
| Total Current Assets
| 318.127 | 266.151 | 77.753 | 110.67 | 130.587 | 30.624 | 7.705 | 10.223 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 0.458 | 1.062 | 1.516 | 0.954 | 0.416 | 0.442 | 0 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0.054 | 0.175 | 0.088 | 0.088 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 7.175 | 4.654 | 3.975 | 1.53 | -0.088 | 2.144 | 0 | 0 |
| Total Non-Current Assets
| 7.633 | 5.716 | 5.545 | 2.659 | 0.416 | 2.674 | 0 | 0 |
| Total Assets
| 325.76 | 271.867 | 83.298 | 113.329 | 131.003 | 33.298 | 7.705 | 10.223 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 1.342 | 0.532 | 3.438 | 2.521 | 0.808 | 1.658 | 0.908 | 0.431 |
| Short Term Debt
| 0 | 0.335 | 0.323 | 0.159 | 0.105 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 5.507 | 2.703 | 0.429 | 0 | 0 | 0 |
| Other Current Liabilities
| 9.422 | 25.027 | 5.954 | 3.073 | 0.565 | 2.54 | 0.924 | 0.395 |
| Total Current Liabilities
| 15.915 | 25.894 | 9.715 | 5.753 | 1.478 | 4.198 | 1.832 | 0.826 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.66 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0.067 | 150.408 | 150.463 | 149.829 | 0.184 | 32.189 | 0 |
| Total Non-Current Liabilities
| 0 | 0.067 | 150.408 | 150.463 | 149.829 | 0.184 | 32.189 | 0.66 |
| Total Liabilities
| 15.915 | 25.961 | 160.123 | 156.216 | 151.307 | 4.382 | 1.832 | 1.486 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0.15 | 0.15 | 0.15 | 0 | 0 | 0 |
| Common Stock
| 0.049 | 0.041 | 0.001 | 0.001 | 0.001 | 0.004 | 0.004 | 0.004 |
| Retained Earnings
| -243.472 | -154.448 | -82.864 | -45.202 | -20.462 | -54.753 | -31.29 | -19.953 |
| Accumulated Other Comprehensive Income/Loss
| 0.055 | 0.141 | -0.15 | -0.016 | 0.004 | 0.032 | 0 | 0 |
| Other Total Stockholders Equity
| 1,106.426 | 400.172 | 6.188 | 2.33 | 0.157 | 5.869 | 4.97 | 4.415 |
| Total Shareholders Equity
| 309.845 | 245.906 | -76.825 | -42.887 | -20.304 | -48.848 | -26.316 | -15.534 |
| Total Equity
| 309.845 | 245.906 | -76.825 | -42.887 | -20.304 | -48.848 | -26.316 | -15.534 |
| Total Liabilities & Shareholders Equity
| 325.76 | 271.867 | 83.298 | 113.329 | 131.003 | 33.298 | 7.705 | 10.223 |